Regular low-dose aspirin use is linked to lower odds of presenting with metastatic colorectal cancer at diagnosis, according to a nationwide Swedish study published in the British Journal of Cancer.
Researchers analyzed data from 81,269 patients diagnosed with primary stage I–IV colorectal cancer in Sweden between 2008 and 2021. Current users of prescribed low-dose aspirin had a 14 percent reduction in the adjusted odds of synchronous distant metastases compared with non-users, the study found.
The association was strongest for tumors originating in the right side of the colon.
Current aspirin users with right-sided colon cancer showed a 21 percent reduction in the odds of metastatic disease, a benefit that also appeared among past users regardless of how long they had taken the drug. No consistent protective effect was observed for left-sided colon malignancies.
Study design and population
The investigation used the Colorectal Cancer Database Sweden (CRCBaSe), which links the Swedish Colorectal Cancer Registry with nationwide health, demographic and prescription registers via unique personal identification numbers. The cohort included all adults diagnosed with a primary colorectal cancer during the study period who had no other cancer diagnosis in the preceding five years.
Exposure was defined as dispensation of at least 365 low-dose aspirin tablets (75 mg or 160 mg) before diagnosis, equivalent to 12 months of use. In Sweden, low-dose aspirin is available only by prescription, which the authors said minimizes misclassification from over-the-counter use.
High-dose aspirin, primarily prescribed or purchased over-the-counter for occasional pain relief and distributed in limited package sizes, accounts for approximately 4 percent of all prescribed aspirin dispensations and was excluded.
Patients were categorized as current users (≥365 tablets dispensed within two years of diagnosis) or past users (met the threshold but not within the two-year window).
The primary outcome was synchronous stage IV disease, identified through the cancer registry and supplemented by the National Patient Register for the 9 percent of cases with missing metastasis data in the SCRCR.
Results by tumor location
The inverse association between aspirin use and metastatic presentation was driven by right-sided colon tumors (cecum, ascending colon, hepatic flexure and transverse colon). For left-sided colon cancer (splenic flexure, descending and sigmoid colon) and rectal cancer, the confidence intervals crossed unity, indicating no statistically significant reduction in metastatic odds.
Sweden, a Nordic country on the Scandinavian Peninsula with 10.6 million people, maintains a universal, tax-funded health-care system and comprehensive population registers linked by unique personal identification numbers.
These registers include the Swedish Colorectal Cancer Registry and the Prescribed Drug Register, which together form the Colorectal Cancer Database Sweden (CRCBaSe) used in the study. Because low-dose aspirin is available only by prescription in Sweden, researchers could track dispensations precisely, minimizing misclassification from over-the-counter use.
No survival benefit found across aspirin duration or dose
Among the 65,177 patients diagnosed from 2011 onward — ensuring at least five years of prescription history — neither duration of use (<3 years, 3 to <5 years, ≥5 years) nor cumulative pill count (<1,095, 1,095 to <1,825, ≥1,825 pills) showed a clear dose-response gradient for the primary outcome. An alternative exposure definition requiring only six months of use yielded similar results. Restricting the analysis to the 2011–2021 cohort did not materially change the estimates.
Global colorectal cancer burden and trial context reviewed
Colorectal cancer is the third most common malignancy and the second leading cause of cancer death worldwide, with about 20 percent of patients presenting with distant metastases at diagnosis. Five-year relative survival remains near 60 percent globally. Previous randomized cardiovascular prevention trials produced conflicting signals on aspirin and metastatic cancer. The ASPREE trial in older adults reported an increased risk of incident metastatic cancer among aspirin users, while pooled analyses of earlier trials found a 31 percent reduction in metastatic adenocarcinoma. The study was approved by the Regional Ethical Board in Stockholm and conducted in Stata v19.
- Pediatric Oncologists in Asia Report Tuberculosis Delays Cancer Diagnosis and Disrupts Treatment
- México Loses Measles Elimination Certification After Year-Long Outbreak, PAHO Says
- Scientists Reveal Eight Kitchen Hacks for Weight Loss and Cancer Prevention (archyde.com)
- Cancer mRNA Vaccines Are on the Horizon (newsylist.com)